Marilena Vrana Reflects on A Year of Growth, Gratitude, and Collective Strength
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared on LinkedIn:
”As the year draws to a close, it offers a natural moment to step back and acknowledge the growth, challenges, and progress that have shaped these past months.
Transitions in leadership are rarely seamless, and stepping into this new role mid-year came with a steep learning curve.
Yet through the transition came a clear lesson: leadership isn’t about having all the answers, but about creating the conditions where collaboration, curiosity, and courage can truly thrive.
This year showed again that resilience is built through collective effort.
The challenges we faced became catalysts for reimagining what’s possible, and our achievements became shared wins that strengthened the sense of purpose across the team, our membership, and the broader community of plasma and plasma-derived medicines.
What has truly fueled me throughout the year is the unwavering dedication of the PPTA Europe staff and members.
Your commitment to the mission, your integrity, and your persistence have shaped not only the milestones we reached, but also the “one-team” culture that continues to take root – grounded in trust, transparency, and shared responsibility.
As the year ends, I am deeply grateful for every colleague, partner, and supporter who contributed to this progress.
Thank you for your patience as I found my footing, for the feedback that sharpened our focus, and for the belief in what we’re building together.
In many ways, I’ve grown not just as a leader, but as a listener, a learner, and a teammate.
The year ahead holds promise with new opportunities, renewed momentum, and continued collaboration.
Here’s to building on this foundation together in the coming year, with purpose and optimism.”
Stay updated with Hemostasis Today.
-
Feb 28, 2026, 12:09Gonzalo Montero Martin: A Breakthrough in HLA Nomenclature for Transplant Evaluation
-
Feb 28, 2026, 11:47Abdul Mannan: Paradox of Bleeding and Clotting in Uremic Coagulopathy
-
Feb 28, 2026, 11:40Jim Hoffman: Could Extracorporeal Removal of NETs Become a ‘Holy Grail’ Therapy Across Multiple Diseases?
-
Feb 27, 2026, 18:30Sanjeev Saksena: From Isolated Case Reports to Clinical Evidence for Post-Ablation Myocardial Ischemia
-
Feb 27, 2026, 18:21Priya Prasad: Can Money Buy Blood?
-
Feb 27, 2026, 18:19Trulee Cardona: Hemophilia Care in Uzbekistan and Why It Matters
-
Feb 27, 2026, 18:19Bartosz Hudzik: Do Elevated Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Otherwise Healthy Women?
-
Feb 27, 2026, 18:14Mohamed Sikkander Abdul Razak: Factor XIa Inhibitors Show Promise With Lower Bleeding Risk
-
Feb 27, 2026, 18:09Hariom Rajput: Early Recognition and Prevention of Deep Vein Thrombosis